PBC

CARLA TULLY APPOINTED TO NIKOLA BOARD OF DIRECTORS

Retrieved on: 
Friday, February 16, 2024

PHOENIX, Feb. 16, 2024 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, via the HYLA brand, today announced the appointment of energy and infrastructure expert Carla Tully, to its Board of Directors. Over more than two decades, Tully has built a successful track record leading and scaling energy organizations across Fortune 150, private equity, startup, and government entities. Tully serves as the Vice Chair of Earthrise Energy's Board of Directors, a Board Director for Citizens for Responsible Energy Solutions Forum and as an Advisor to several energy transition startups.

Key Points: 
  • PHOENIX, Feb. 16, 2024 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, via the HYLA brand , today announced the appointment of energy and infrastructure expert Carla Tully, to its Board of Directors .
  • Tully serves as the Vice Chair of Earthrise Energy's Board of Directors, a Board Director for Citizens for Responsible Energy Solutions Forum and as an Advisor to several energy transition startups.
  • "As Nikola scales its energy infrastructure business, especially in the hydrogen ecosystem, the addition of Carla to Nikola's Board of Directors will greatly benefit our company, employees and shareholders," said Steve Shindler, Chairman of Nikola's Board of Directors.
  • I've dedicated my career to similar missions, and I am delighted to join Nikola's Board of Directors and support Nikola in 2024 and beyond."

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

Retrieved on: 
Thursday, February 15, 2024

Total revenues in the fourth quarter of 2023 were $117.6 million, compared to $107.2 million in the fourth quarter of 2022.

Key Points: 
  • Total revenues in the fourth quarter of 2023 were $117.6 million, compared to $107.2 million in the fourth quarter of 2022.
  • Operating expenses in the fourth quarter of 2023 were $80.0 million, compared to $38.8 million in the fourth quarter of 2022.
  • Adjusted EBITDA was $39.9 million in the fourth quarter of 2023, compared to $68.7 million in the fourth quarter of 2022.
  • Ironwood generated $35.8 million in cash from operations in the fourth quarter of 2023, compared to $79.2 million in cash from operations in the fourth quarter of 2022.

Aniq Ahmad Joins Opportune as Managing Director and President of the Firm’s Outsourcing Practice

Retrieved on: 
Wednesday, February 14, 2024

Opportune LLP, a leading global business advisory firm, is pleased to announce that Aniq Ahmad has joined the firm as Managing Director and President of Outsourcing.

Key Points: 
  • Opportune LLP, a leading global business advisory firm, is pleased to announce that Aniq Ahmad has joined the firm as Managing Director and President of Outsourcing.
  • Mr. Ahmad brings 20 years of energy industry experience to Opportune where his primary focus will be managing the firm’s Outsourcing practice.
  • View the full release here: https://www.businesswire.com/news/home/20240214123879/en/
    Aniq Ahmad | Opportune LLP (Photo: Business Wire)
    “Aniq brings a wealth of experience and strategic vision to Opportune,” remarked David Baggett , Managing Partner.
  • “I am thrilled to be joining Opportune, a firm renowned for its commitment to excellence and client success,” said Mr. Ahmad.

Satellite Data Services Market worth $20.9 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, February 14, 2024

Overcoming these challenges while capitalizing on the growing demand for satellite data services will be crucial for sustaining market growth and fostering innovation in the years ahead.

Key Points: 
  • Overcoming these challenges while capitalizing on the growing demand for satellite data services will be crucial for sustaining market growth and fostering innovation in the years ahead.
  • Based on the vertical, the Defense & Security segment is estimated to lead the Satellite Data Services Market from 2023 to 2028.
  • In 2023, the commercial segment is anticipated to dominate the Satellite Data Services market, holding the largest market share.
  • This includes high-resolution imaging sensors, small satellite constellations, and data analytics platforms, driving the growth of satellite data services in the region.

Satellite Data Services Market worth $20.9 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, February 14, 2024

Overcoming these challenges while capitalizing on the growing demand for satellite data services will be crucial for sustaining market growth and fostering innovation in the years ahead.

Key Points: 
  • Overcoming these challenges while capitalizing on the growing demand for satellite data services will be crucial for sustaining market growth and fostering innovation in the years ahead.
  • Based on the vertical, the Defense & Security segment is estimated to lead the Satellite Data Services Market from 2023 to 2028.
  • In 2023, the commercial segment is anticipated to dominate the Satellite Data Services market, holding the largest market share.
  • This includes high-resolution imaging sensors, small satellite constellations, and data analytics platforms, driving the growth of satellite data services in the region.

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024

Retrieved on: 
Wednesday, February 14, 2024

United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 21, 2024.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 21, 2024.
  • United Therapeutics will host a public webcast Wednesday, February 21, 2024, at 9:00 a.m. Eastern Time.
  • The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations .
  • We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

Zevia to Announce Fourth Quarter and Full Year 2023 Results on Tuesday, February 27, 2024

Retrieved on: 
Tuesday, February 13, 2024

Zevia PBC (“Zevia”) (NYSE:ZVIA) today announced that it will release its financial results for the fourth quarter and full year 2023 ended December 31, 2023 before the market open on Tuesday, February 27, 2024 followed by a conference call at 8:30 a.m. Eastern Time to discuss the results.

Key Points: 

Zevia PBC (“Zevia”) (NYSE:ZVIA) today announced that it will release its financial results for the fourth quarter and full year 2023 ended December 31, 2023 before the market open on Tuesday, February 27, 2024 followed by a conference call at 8:30 a.m. Eastern Time to discuss the results.

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

Retrieved on: 
Monday, February 12, 2024

Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.
  • View the full release here: https://www.businesswire.com/news/home/20240211034242/en/
    “We are looking forward to advancing seladelpar by leveraging Gilead’s long-standing expertise in treating and curing liver diseases,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences.
  • Seladelpar is an investigational, oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist, shown to regulate critical metabolic and liver disease pathways.
  • “Today’s agreement with Gilead is the culmination of years of focus and determination at CymaBay to advance seladelpar and bring new hope to people living with PBC and their families,” said Sujal Shah, President, and CEO at CymaBay Therapeutics.

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

Retrieved on: 
Monday, February 12, 2024

NEWARK, Calif., Feb. 12, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for seladelpar, an investigational treatment for the management of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid. The FDA has granted priority review and set a Prescription Drug User Fee Act (PDUFA) target action date of August 14, 2024 and notified the company that it is not currently planning to hold an advisory committee meeting to discuss the application.

Key Points: 
  • PBC is a rare, chronic condition that can lead to inflammation and eventually liver cirrhosis.
  • People living with PBC can also experience symptoms that significantly impact their quality of life such as pruritus (itch) and fatigue.
  • Seladelpar is an investigational, potent, selective, orally active PPARδ agonist, or delpar, in development for PBC treatment.
  • "We are encouraged by the agency's decision to grant priority review for seladelpar, and its recognition of the significant need for new treatment options for people living with PBC.

24th Edition of CFO Leadership Summit: KSA

Retrieved on: 
Monday, February 12, 2024

RIYADH, Feb 12, 2024 - (ACN Newswire) - The 24th edition of the CFO Leadership Summit is set to unite financial luminaries and industry leaders on February 14th, 2024, in Riyadh, Saudi Arabia.

Key Points: 
  • RIYADH, Feb 12, 2024 - (ACN Newswire) - The 24th edition of the CFO Leadership Summit is set to unite financial luminaries and industry leaders on February 14th, 2024, in Riyadh, Saudi Arabia.
  • Beyond thought-provoking conversations and networking opportunities, the 24th CFO Summit will unveil the CFO 50 winners.
  • The CFO Leadership Summit compiles the annual CFO 50 list by considering nominations, direct applications, information from an extensive database, insightful interviews, scrutiny of company websites, and other publicly available sources.
  • Exito Media Concepts, the force behind the CFO Summit, takes pride in facilitating this platform for learning, collaboration, and celebration.